Clearasil leads company’s acne medication portfolio
Reckitt Benckiser Group (RB) took over Clearasil and its associated portfolio nearly two decades ago. RB gradually reduced Clearasil's product portfolio to the Ultra line and launched the Daily Clear line. After starting out with a teen-focused, treatment-only product portfolio, Clearasil currently offers a range of products for rapid pimple treatment and everyday prevention catering to teens aged 11 to 17 and young adults aged 18 to 24. Clearasil is the only brand in the United States that sources its sales equally from male and female consumers. In 2020, RB announced its intention to divest Clearasil among other brands, though no sale has been made to date.
Structural|Discontinued ActivityIn response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.
Lorem Ipsum text header Report Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.
Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.